Download PDF
Hamostaseologie 1985; 05(05/06): 185-192
DOI: 10.1055/s-0038-1655127
Originalarbeiten
Schattauer GmbH

Thrombose und Blutungsneigung bei myeloproliferativen Erkrankungen[*]

A. Wehmeier
1   Abteilung für Hämatologie, Onkologie und klinische Immunologie, Medizinische Universitätsklinik Düsseldorf
,
R. E. Scharf
1   Abteilung für Hämatologie, Onkologie und klinische Immunologie, Medizinische Universitätsklinik Düsseldorf
,
W. Schneider
1   Abteilung für Hämatologie, Onkologie und klinische Immunologie, Medizinische Universitätsklinik Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

 

* Mit Unterstützung der Deutschen Forschungsgemeinschaft (We 1072).


 

  • LITERATUR

  • 1 Adams T, Schutz L, Goldberg L. Platelet function abnormalities in the myeloproliferative disorders. Scand. J. Haematol. 13: 215-224 1974;
    PubMedGoogle Scholar
  • 2 Adamson J. W. R, Fialkow J, Murphy S, Prchal J. F, Steinmann L. Polycythemia vera: Stem-cell and probable clonal origin of the disease. New Engl. J. Med. 295: 913-916 1976;
    CrossrefPubMedGoogle Scholar
  • 3 Akkerman J-WN, Nieuwenhuis H. K, Mommersteeg-Leautaud M. E, Gorter G, Sixma J. J. ATP/ADP compartmentation in storage pool deficient platelets: correlation between granule-bound ADP and the bleeding time. Brit. J. Haematol. 55: 135-143 1983;
    CrossrefPubMedGoogle Scholar
  • 4 Barbui T, Battista R, Dini E. Spontaneous platelet aggregation in myeloproliferative disorders. Acta haemat. 50: 25-29 1973;
    CrossrefPubMedGoogle Scholar
  • 5 Berk P. D, Goldberg J. D, Silverstein M. N. et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. New Engl. J. Med. 304: 441-447 1981;
    CrossrefPubMedGoogle Scholar
  • 6 Berlin N. I. Diagnosis and classification of the polycythemias. Sem. Haematol. 12: 339-351 1975;
    PubMedGoogle Scholar
  • 7 Bolin R. B, Okumura T, Jamieson G. A. Changes in distribution of platelet membrane glycoproteins in patients with myeloproliferative disorders. Amer. J. Hematol. 03: 63-71 1977;
    CrossrefPubMedGoogle Scholar
  • 8 Boneu B, Nouvel C, Sie P, Caranobe C, Combes D, Laurent G, Pris J, Bierme R. Platelets in myeloproliferative disorders I. A comparative evaluation with certain platelet function tests. Scand. J. Haematol. 25: 214-220 1980;
    PubMedGoogle Scholar
  • 9 Boneu B, Sie P, Eche N, Caranobe C, Hugo B, Nouvel C. Platelet density analysis: A tool for the detection of acquired storage pool disease in man. Brit. J. Haematol. 55: 523-532 1983;
    CrossrefPubMedGoogle Scholar
  • 10 Born G. V. R. Fluid-mechanical and biochemical interactions in hemostasis. Brit. Med. Bull. 33: 193-197 1977;
    CrossrefPubMedGoogle Scholar
  • 11 Born G. V. R, Wehmeier A. Inhibition of platelet thrombus formation by chlorpromazine acting to diminish haemolysis. Nature. 282: 212-213 1979;
    CrossrefPubMedGoogle Scholar
  • 12 Boughton B. J. Chronic myeloproliferative disorders: improved platelet aggregation following venesection. Brit. J. Haematol. 39: 589-598 1978;
    CrossrefPubMedGoogle Scholar
  • 13 Boughton B. J, Allington M. J, King A. Platelet and plasma ß thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Brit. J. Haematol. 40: 125-132 1978;
    CrossrefPubMedGoogle Scholar
  • 14 Boughton B. J, Corbett W. E. N, Ginsburg A. D. Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. J. clin. Pathol. 30: 228-234 1977;
    CrossrefPubMedGoogle Scholar
  • 15 Boughton B. J, Dallinger U, Barrow S, Chappell C. Prostaglandin/Thromboxane synthesis and storage ADP determine the in vitro platelet aggregation response in chronic myeloproliferative syndromes. Xth Int. Cong. Thromb. Haemost., San Diego. Thromb. Haemost. 54: 71 1985;
    PubMedGoogle Scholar
  • 16 Burstein S. A, Malpass T. W, Yee E, Kadin M, Bridgen M, Adamson J. W, Harker L. A. Platelet factor 4 excretion in myeloproliferative disease : implications for the aetiology of myelofibrosis. Brit. J. Haematol. 57: 383-392 1984;
    CrossrefPubMedGoogle Scholar
  • 17 Cappio F. C, Vigliano R, Novarino A, Camussi G, Campano D, Gavosto F. Idiopathic myelofibrosis: a possible role for immune complexes in the pathogenesis of bone marrow fibrosis. Brit. J. Haematol. 49: 17-21 1981;
    CrossrefPubMedGoogle Scholar
  • 18 Caranobe C, Sie P, Fernandez F, Pris J, Moatti S, Boneu B. Abnormal platelet serotonin uptake and binding sites in myeloproliferative disorders. Thromb. Haemost. 51: 349-353 1984;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Caranobe C, Sie P, Laurent G, Pris J, Boneu B. Platelets in myeloproliferative disorders: II. Serotonin uptake and storage: correlation with mepacrine labelled dense bodies and with platelet density. Scand. J. Haematol. 25: 289-295 1980;
    PubMedGoogle Scholar
  • 20 Carbonell F, Ganser A, Heimpel H. Cytogenetic studies in chronic myeloproliferative disorders. Acta haematol. 69: 145-151 1983;
    CrossrefPubMedGoogle Scholar
  • 21 Cardamone J. M, Edson J. R, McArthur J. R, Jacob H. S. Abnormalities of platelet function in the myeloproliferative disorders. JAMA. 221: 270-273 1972;
    CrossrefPubMedGoogle Scholar
  • 22 Champlin R. E, Golde D. W. Chronic myelogenous leukemia: recent advances. Blood. 65: 1039-1047 1985;
    PubMedGoogle Scholar
  • 23 Cooper B, Schafer A. I, Puchalsky D, Handin R. I. Platelet resistance to prostaglandin D2 in patients with myeloproliferative disorders. Blood. 52: 618-626 1978;
    PubMedGoogle Scholar
  • 24 Cortelazzo S, Barbui T, Bassan R, Dini E. Abnormal aggregation and increased size of platelets in myeloproliferative disorders. Thromb. Haemost. 43: 127-130 1980;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Cortelazzo S, Viero P, Bassan R, Barbui F. Spectrum of platelet aggregation abnormalities in myeloproliferative diseases. La Ric. Clin. Lab. 11: 35-42 1981;
    PubMedGoogle Scholar
  • 26 Cunietti E, Gandini R, Mascaro G, Ferrari M, Pappalepore V, Scapellato C. Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases. Scand. J. Haematol. 26: 339-344 1981;
    PubMedGoogle Scholar
  • 27 Dameshek W. Some speculations on the myeloproliferative syndrome. Blood. 06: 372-375 1951;
    PubMedGoogle Scholar
  • 28 Dormandy J. A. Haemorheological aspects of thrombosis. Brit. J. Haematol. 45: 519-522 1980;
    CrossrefPubMedGoogle Scholar
  • 29 Fialkow P. J, Faguet G. B, Jacobson R. J, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 58: 916-919 1981;
    PubMedGoogle Scholar
  • 30 Fialkow P. J, Jacobson R. J, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer. J. Med. 63: 125-130 1977;
    CrossrefPubMedGoogle Scholar
  • 31 Fischer T. M. Mechanisches Verhalten von Erythrozyten im Scherfeld zäher Lösungen. Dissertation, Aachen. 1978
    PubMedGoogle Scholar
  • 32 Gerrard J. M, Stoddard S. F, Shapiro R. S, Coccia P. F, Ramsay N. K. C, Nesbit M. E, Rao G. H. R, Krivit W, White J. G. Platelet storage pool deficiency and prostaglandin synthesis in chronic granulocytic leukemia. Brit. J. Haematol. 40: 597-607 1978;
    CrossrefPubMedGoogle Scholar
  • 33 Ginsburg A. D. Platelet function in patients with high platelet counts. Ann. Int. Med. 82: 506-511 1975;
    CrossrefPubMedGoogle Scholar
  • 34 Goldfinger D, Thompson R, Lowe C, Kurz L, Belkin G. Long-term plateletpheresis in the management of primary thrombocytosis. Transfusion. 19: 336-338 1979;
    CrossrefPubMedGoogle Scholar
  • 35 Goldsmith H. L. Red Cell motions and wall interactions in tube flow. Fed. Proc. 30: 1578-1590 1971;
    PubMedGoogle Scholar
  • 36 Harrison M. J. G, Mitchell J. R. A. The influence of red cells on platelet adhesiveness. Lancet. II: 1163-1164 1966;
    PubMedGoogle Scholar
  • 37 Hasselbalch H, Berild D, Hansen O. P. Platelet-associated IgG and IgM in myelofibrosis. Scand. J. Haematol. 32: 488-492 1984;
    PubMedGoogle Scholar
  • 38 Hoagland H. C, Silverstein M. N. Primary thrombocythemia in the young patient. Mayo Clin. Proc. 53: 578-580 1978;
    PubMedGoogle Scholar
  • 39 Holme S, Murphy S. Studies of the platelet density abnormality in myeloproliferative disease. J. Lab. Clin. Med. 103: 373-383 1984;
    PubMedGoogle Scholar
  • 40 Holme S, Simmonds M, Ballek R, Murphy S. Comparative measurements of platelet size by Coulter Counter, microscopy of blood smears, and light-transmission studies. J. Lab. Clin. Med. 97: 610-622 1981;
    PubMedGoogle Scholar
  • 41 Humphrey P. R. D, DuBoulay G. H, Marshall J, Pearson T. C, Russell R. W. R, Symon L, Wetherley-Mein G, Zilkha E. Cerebral blood flow and viscosity in relative polycythemia. Lancet. II: 873-876 1979;
    PubMedGoogle Scholar
  • 42 Jabaily J, Iland H. J, Laszlo J, Massey E. W, Faguet G. B, Briere J, Landaw S. A, Pisciotta A. V. Neurologic manifestations of essential thrombocythemia. Ann. Intern. Med. 99: 513-518 1983;
    CrossrefPubMedGoogle Scholar
  • 43 Jacobson R. J, Salo A, Fialkow P. J. Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 51: 189-194 1978;
    PubMedGoogle Scholar
  • 44 Jubelirer S. J, Russell F, Vaillancourt R, Deykin D. Platelet arachidonic acid metabolism and platelet function in ten patients with chronic myelogenous leukemia. Blood. 56: 728-731 1980;
    PubMedGoogle Scholar
  • 45 Kaywin P, McDonough M, Insel P. A, Shattil S. J. Platelet function in essential thrombocythemia: decreased epinephrine responsiveness associated with a deficiency of platelet-adrenergic receptors. New Engl. J. Med. 299: 505-509 1978;
    CrossrefPubMedGoogle Scholar
  • 46 Keenan J. P, Wharton J, Sheperd A. N. J, Bellingham A. J. Defective platelet lipid peroxydation in myeloproliferative disorders : a possible defect of prostaglandin synthesis. Brit. J. Haematol. 35: 275-283 1977;
    CrossrefPubMedGoogle Scholar
  • 47 Kessler C. M, Klein H. G, Havlik R. J. Uncontrolled thrombocytosis in myeloproliferative disorders. Brit. J. Haematol. 50: 157-167 1982;
    CrossrefPubMedGoogle Scholar
  • 48 Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Sem. Hematol. 12: 409-432 1975;
    PubMedGoogle Scholar
  • 49 Lewis C. M, Pegrum G. D. Immune complexes in myeloproliferative disorders. Lancet. II: 1151-1153 1977;
    PubMedGoogle Scholar
  • 50 Maldonado J. E, Pintado T, Pierre R. V. Dysplastic platelets and circulating megakaryocytes in chronic myeloproliferative diseases. I. The platelets: Ultrastructure and peroxydase reaction. Blood. 43: 797-809 1974;
    PubMedGoogle Scholar
  • 51 Martinez J, Shapiro S. S, Holburn R. R. Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states. Blood. 42: 35-46 1973;
    PubMedGoogle Scholar
  • 52 Mason jr J. R, De Vita V. T, Canellos G. P. Thrombocytosis in chronic granulocytic leukemia: Incidence and clinical significance. Blood. 44: 483-487 1974;
    PubMedGoogle Scholar
  • 53 Mittal R. R, Meisler A. I. Spontaneous massive abdominal wall hematoma in polycythemia vera. Acta haemat. 72: 128-130 1984;
    CrossrefPubMedGoogle Scholar
  • 54 Moore A, Nachman R. L. Platelet Fc receptor. Increased expression in myeloproliferative disease. J. Clin. Invest. 67: 1064-1071 1981;
    PubMedGoogle Scholar
  • 55 Murphy S, Davis J. L, Walsh P. N, Gardner F. H. Template bleeding time and clinical hemorrhage in myeloproliferative disease. Arch. Intern. Med. 138: 1251-1253 1978;
    CrossrefPubMedGoogle Scholar
  • 56 Najean Y, Poirier O, Lokiec F. The clinical significance of beta-thromboglobulin and platelet factor 4 in polycythemic patients. Scand. J. Haematol. 31: 298-304 1983;
    PubMedGoogle Scholar
  • 57 Neemeh J. A, Bowie E. J. W, Thompson B. C. J, Didisheim D, Owen jr C. A. Quantitation of platelet aggregation in myeloproliferative disorders. Amer. J. clin. Pathol. 57: 336-347 1972;
    PubMedGoogle Scholar
  • 58 Nishimura J, Okamoto S, Ibayashi H. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders. Thromb. Haemost. 41: 787-795 1979;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Okuma M, Uchino H. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Blood. 54: 1258-1271 1979;
    PubMedGoogle Scholar
  • 60 Panilio A. L, Reiss R. F. Therapeutic plateletpheresis in thrombocythemia. Transfusion. 19: 147-152 1979;
    CrossrefPubMedGoogle Scholar
  • 61 Pareti F. I, Gugliotta L, Mannucci L, Guarini A, Mannucci P. M. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disease. Thromb. Haemost. 47: 84-89 1982;
    PubMedGoogle Scholar
  • 62 Patscheke H, Stegmeier K. Investigations on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb. Res. 33: 277-288 1984;
    CrossrefPubMedGoogle Scholar
  • 63 Pearce J. M. S, Chandrasekera C. P, Ladusans E. J. Lacunar infarcts in polycyt- haemia with raised packed cell volumes. Brit. Med. J. 287: 935-936 1983;
    CrossrefPubMedGoogle Scholar
  • 64 Pearson T. C, Wetherly-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycyt- haemia. Lancet. II: 1219-1222 1978;
    PubMedGoogle Scholar
  • 65 Penington D. G, Streatfield K, Roxburgh A. E. Megakaryocytes and the heterogeneity of circulating platelets. Brit. J. Haematol. 34: 639-653 1976;
    CrossrefPubMedGoogle Scholar
  • 66 Preston F. E, Emmanuel I. G, Winfield D. A, Malia R. G. Essential thrombocythemia and peripheral gangrene. Brit. Med. J. 03: 548-552 1974;
    CrossrefPubMedGoogle Scholar
  • 67 Rao A. K, Walsh P. N. Acquired qualitative platelet disorders. Clin. Haematol. 12: 201-238 1983;
    PubMedGoogle Scholar
  • 68 Rendu F, Lebret M, Nurden A, Caen J. P. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb. Haemost. 42: 794-796 1979;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Rhyner K. Einsatz thrombozytenfunk- tionshemmender Medikamente bei primärer Thrombozythämie. In: Bollinger A, Rhyner K. (Hrsg.): Thrombozytenfunktionshemmer : Wirkungsmechanismen, Dosierung und praktische Anwendung. Symposium Zürich. Thieme: Stuttgart; 1983: 59-66.
    Google Scholar
  • 70 Ross R, Glomset J, Kariya B, Harker L. A. A platelet dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc. Natl. Acad. Sci. (USA). 71: 1207-1210 1974;
    CrossrefPubMedGoogle Scholar
  • 71 Russell N. H, Salmon J, Keenan J. P, Bellingham A. J. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative syndrome. Thromb. Res. 22: 389-397 1981;
    CrossrefPubMedGoogle Scholar
  • 72 Schafer A. I. Deficiency of platelet lipoxygenase activity in myeloproliferative disorders. New Engl. J. Med. 306: 381-386 1982;
    CrossrefPubMedGoogle Scholar
  • 73 Schafer A. I. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 64: 1-12 1984;
    PubMedGoogle Scholar
  • 74 Scharf R. E, Theis O, Schneider W. Plättchensekretion und Thrombinaktivität bei Malignompatienten. Hämostaseologie. 05: 166-169 1985;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 75 Schmid-Schönbein H. Microrheology of erythrocytes and thrombocytes. Blood viscosity and the distribution of blood flow in the microcirculation. In: Meessen H. (Hrsg.): Handbuch der allgemeinen Pathologie III/7: Microzirkulation. Springer: Berlin, Heidelberg; 1977: 289-384.
    Google Scholar
  • 76 Scrutton M. C, Wallis R. B. Catecholamine receptors. In: Gordon J. L. (Ed.): Platelets in Biology and Pathology. Elsevier/North Holland Biomedical Press; Amsterdam: 1981
    Google Scholar
  • 77 Semeraro N, Cortelazzo S, Colucci M, Barbui T. A hitherto undescribed defect of platelet coagulant activity in polycythemia vera and essential thrombocythemia. Thromb. Res. 16: 795-802 1979;
    CrossrefPubMedGoogle Scholar
  • 78 Small B. M, Bettigole R. E. Diagnosis of myeloproliferative disease by analysis of the platelet volume distribution. Am. J. Clin. Pathol. 76: 685-691 1981;
    CrossrefPubMedGoogle Scholar
  • 79 Smith I. L, Martin T. J. Platelet thromboxane synthesis and release reactions in myeloproliferative disorders. Haemostasis. 11: 119-127 1982;
    PubMedGoogle Scholar
  • 80 Spaet HTh, Lejnieks I, Gaynor E, Goldstein M. L. Defective platelets in essential thrombocythemia. Arch. Intern. Med. 124: 135-141 1969;
    CrossrefPubMedGoogle Scholar
  • 81 Stathakis N. E, Papayannis A. G, Arapakis G, Gardikas C. Haemostatic defects in polycythemia vera. Blut. 29: 77-86 1974;
    CrossrefPubMedGoogle Scholar
  • 82 Swart S. S, Pearson D, Wood J. K, Barnett D. B. Functional significance of the platelet alpha-2-adrenoceptor: studies in patients with myeloproliferative disorders. Thromb. Res. 33: 531-541 1984;
    CrossrefPubMedGoogle Scholar
  • 83 Thiele J, Holgado H, Choritz H, Georgii A. Density distribution and size of megakaryocytes in inflammatory reactions of the bone marrow (myelitis) and chronic myeloproliferative diseases. Scand. J. Haematol. 31: 329-431 1983;
    PubMedGoogle Scholar
  • 84 Turitto V. T. Blood viscosity, mass transport, and thrombogenesis. Prog. Hemost. Thromb. 06: 139-177 1982;
    PubMedGoogle Scholar
  • 85 Vainer H, Bussel A. Glycoproteines de surface alterees des plaquettes de leucemie myeloide chronique. Int. J. Cancer. 19: 143-149 1977;
    CrossrefPubMedGoogle Scholar
  • 86 Viero P, Cortelazzo S, Bassan R, Barbui T. Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases. Thromb. Haemost. 48: 125-126 1982;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 Vreeken J, van Aken W. G. Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet. II: 1394-1397 1971;
    PubMedGoogle Scholar
  • 88 Waddell C. C, Brown J. A, Repinecz Y. A. Abnormal platelet function in myeloproliferative disorders. Arch. Pathol. Lab. Med. 105: 432-435 1981;
    PubMedGoogle Scholar
  • 89 Walsh P. N, Murphy S, Barry W. E. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thromb. Haemost. 38: 1085-1096 1977;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Wasserman L. R, Gilbert H. S. Complications of polycythaemia vera. Sem. Hematol. 03: 199-208 1966;
    PubMedGoogle Scholar
  • 91 Wasserman L. R, Goldberg J. D, Balcerak S. P, Berk P. D, Donovan P. B, Dresch C, Ellis J. T, Landaw S. A, Laszlo J, McIntyre O. R, Najean Y, Pisciotta A. V, Silverstein M, Tartaglia A. P, Tatarsky I, Weinfeld A. Influence of therapy on causes of death in polycythemia vera. Clin. Res. 29: 573A 1981;
    PubMedGoogle Scholar
  • 92 Wehmeier A, Fricke S, Scharf R. E, Schneider W. Influence of therapy on platelet activation and thrombin generation in myeloproliferative disease. Xth Int. Cong. Thromb. Haemost., San Diego. Thromb. Haemost. 54: 128 1985;
    PubMedGoogle Scholar
  • 93 Wehmeier A, Scharf R. E, Planker M, Schneider W. Inhalt der Plättchengranula und intravasale Thrombinaktivität bei myeloproliferativen Erkrankungen. Jahrestagung d. Dtsch. u. österr. Ges. Hämatol. Onkol., Ulm. Blut. 49: 232 1984;
    PubMedGoogle Scholar
  • 94 Wehmeier A, Schneider W. Thrombozytenfunktionshemmung als therapeutisches und prophylaktisches Prinzip. Inn. Med. 12: 187-203 1985;
    PubMedGoogle Scholar
  • 95 Weinfeld A, Branehög I, Kutti J. Platelets in the myeloproliferative syndrome. Clin. Haematol. 04: 373-392 1975;
    PubMedGoogle Scholar
  • 96 Witte L. D, Kaplan K. L, Nossel H. L, Lages B. A, Weiss H. J, Goodman D. S. Studies of the release from human platelets of the growth factor for cultured human arterial smooth muscle cells. Circ. Res. 42: 402-409 1978;
    CrossrefPubMedGoogle Scholar
  • 97 Wu K. Y. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann. Intern. Med. 88: 7-11 1978;
    CrossrefPubMedGoogle Scholar
  • 98 Yamamoto K, Sekiguchi E, Takatani O. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb. Haemost. 52: 292-296 1984;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Zeigler Z, Murphy S, Gardner F. H. Microscopic platelet size and morphology in various hematologic disorders. Blood. 51: 479-486 1978;
    PubMedGoogle Scholar
  • 100 Zucker S, Mielke C. H. Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications. J. Lab. Clin. Med. 80: 385-394 1972;
    PubMedGoogle Scholar